PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-37.55%
Both yoy net incomes decline, with AXSM at -498.77%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
14.84%
Some D&A expansion while AXSM is negative at -30.41%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
No Data
No Data available this quarter, please select a different quarter.
0.81%
Less SBC growth vs. AXSM's 23.02%, indicating lower equity issuance. David Dodd would confirm the firm still retains key staff.
106.29%
Slight usage while AXSM is negative at -37.41%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
81.80%
Some yoy usage while AXSM is negative at -31.12%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
No Data
No Data available this quarter, please select a different quarter.
9.51%
Some CFO growth while AXSM is negative at -850.85%. John Neff would note a short-term liquidity lead over the competitor.
38.16%
Some CapEx rise while AXSM is negative at -87.32%. John Neff would see competitor possibly building capacity while we hold back expansions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
38.16%
We have mild expansions while AXSM is negative at -87.32%. John Neff sees competitor possibly divesting or pausing expansions more aggressively.
No Data
No Data available this quarter, please select a different quarter.
1171.17%
Lower share issuance yoy vs. AXSM's 58039.53%, implying less dilution. David Dodd would confirm the firm still has enough capital for expansions.
No Data
No Data available this quarter, please select a different quarter.